Sign in

    Boobalan Pacha

    Wall Street Analyst currently serving as an Equity Research Analyst at H.C. Wainwright & Co.

    Boobalan Pachaiyappan is a Wall Street Analyst currently serving as an Equity Research Analyst at Roth MKM (formerly Roth Capital), specializing in coverage of small and mid-cap biotech and pharmaceutical companies such as CervoMed, Galera Therapeutics, Galecto, Reviva Pharmaceuticals, Cingulate, and Ensysce Biosciences. He has issued multiple ratings, with his most profitable being a buy on CervoMed that achieved a 326% return; however, his overall TipRanks success rate stands at 28.6% with a total average return of -10.1% over the past year. Pachaiyappan began his analyst career prior to joining Roth MKM and has built a focus in clinical-stage therapeutics, regularly adjusting price targets and ratings based on clinical trial and development outcomes. His professional credentials likely include necessary securities licenses and FINRA registration, as is standard for equity research analysts at major brokerages.

    Boobalan Pacha's questions to Addex Therapeutics (ADXN) leadership

    Boobalan Pacha's questions to Addex Therapeutics (ADXN) leadership • Q1 2023

    Question

    Boobalan Pacha of H.C. Wainwright & Co. inquired about the implications of the positive recommendation to continue the Phase II trial for ADX-71149 and asked for an update on partnership efforts for Dipraglurant.

    Answer

    Executive Timothy Dyer explained that the recommendation from the independent review committee to continue the ADX-71149 study is very positive, suggesting the drug is safe and potentially effective, which increases the probability of a successful outcome. Regarding Dipraglurant, he confirmed that discussions with multiple potential partners are ongoing across the entire portfolio, but could not provide specific details on progress.

    Ask Fintool Equity Research AI